Open Philanthropy recommended an investment of $3,000,000 in Eiger InnoTherapeutics, a new company founded by Professor Jeffrey S. Glenn, that has acquired the rights to two drugs, lonafarnib and pegylated interferon lambda. The company will develop Lonafarnib for use against hepatitis D, for which there is no FDA-approved drug for HDV, the worst form of human viral hepatitis.
Interferon Lambda has demonstrated broad-spectrum antiviral activity. The company will seek to work in collaboration with the FDA and other regulatory authorities to address multiple important high unmet needs using interferon lambda.
This investment was funded via our request for proposals through the Pandemic Antiviral Discovery Initiative.
This falls within our focus area of scientific research.